March of approvals for cabozantinib continues with first-line kidney cancer nod

17 May 2018

French pharma firm Ipsen (Euronext: IPN) is trading about 2% higher in Paris today, on news that Cabometyx (cabozantinib), which targets multiple receptors implicated in cancer, has been approved for the first-line treatment of certain kidney cancer patients in Europe.

Co-developer Exelixis (Nasdaq: EXEL), which discovered the compound and entered into an extensive commercialization and development deal with Ipsen in 2016, also saw its share rise significantly ahead of the opening bell in New York. Japanese pharma major Takeda (TYO: 4502) holds the rights to sell the drug in Japan.

Ipsen's commercial chief Harout Semerjian called the approval “a step forward for advanced kidney cancer patients in Europe who will be able to access a new oral first-line treatment option that offers significant improvement over the standard of care.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK